U.S. Obesity Market Analysis: Exploring Demographic & Geographic Disparities in GLP-1 Use [Video]

Photo Credit: PeopleImages.com – Yuri A / Shutterstock

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) work by mimicking a natural hormone that regulates both appetite and blood sugar. By reducing hunger and promoting a feeling of fullness, these drugs have been shown to facilitate significant weight loss, with many patients shedding 15% or more of their body weight.

The efficacy of GLP-1s has made them a breakthrough not only in managing obesity and diabetes, but also in their potential to treat several related conditions. According to IRIS—a proprietary market intelligence platform developed by Real Chemistry—GLP-1s could show efficacy and safety in as many as 20 therapeutic areas in the next 10 years. This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease, PCOS, and more.

Despite their benefits, access …